01
Company2026-05-10
Shuaizhijia Group signs strategic MOU with Nordic pharmaceutical company
The partnership will cover product introduction, registration coordination and commercialization in cardiovascular therapeutics.
AllCompanyIndustryMedia
02
Industry2026-04-28
China regulatory reform opens new window for cross-border pharma partnerships
NMPA's latest policies shorten review timelines for certain imported drugs, offering clearer scheduling for cross-border partners.
03
Company2026-04-18
Shuaizhijia Group upgrades European partnership platform
The platform will use the Beijing Changping Vanke Sky City office hub to improve coordination across product partnerships, regulatory affairs and commercialization.
04
Industry2026-03-29
Cross-border pharma supply chains enter a new quality-and-efficiency era
Compliance, traceability and reliable delivery are becoming core partner selection criteria.
05
Company2026-03-15
RegPath Navigator regulatory platform completes beta and goes live
The platform initially serves 5 active partnership projects spanning registration planning, regulatory tracking and bilingual documentation.
06
Media2026-02-28
Interview: How Shuaizhijia Group puts pharmaceutical 'long-termism' into practice
From three-year commercialization roadmaps to sustained compliance investment, the leadership explains their methodology for long-term partnership building.
07
Media2026-02-14
Media spotlight: How a European-backed group serves China's healthcare market
Leadership discussed the Beijing hub, global resources, local teams and long-term commitment.
08
Industry2026-01-20
2025 in review: Five trends shaping cross-border pharma supply chains
Digital traceability, cold-chain upgrades, compliance-by-design, regional coordination and risk diversification defined the year.